ArticlePsycho-oncology2026
Validation of the Double Awareness Scale: A Novel Measure of Psychological Adaptation to Advanced Cancer.
Article in Psycho-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIndividuals with advanced cancer face the challenge of remaining engaged in life, while also contemplating death. However, there has been no validated measure of the adaptive capacity to balance these tasks, which has been termed "double awareness."
aimsThis study aimed to evaluate the psychometric properties of the novel Double Awareness Scale (DAS).
methodsPatients with advanced cancer attending an outpatient palliative care clinic (N = 197) completed the DAS and other self-report measures assessing quality of life near end of life, life completion, satisfaction with life, preparation for end of life, death anxiety, and depression. Factor structure, construct validity, and internal consistency of the DAS were evaluated, as were group differences across high, intermediate, and low levels of double awareness.
resultsFactor analysis supported two factors, Life Engagement and Death Contemplation, with high internal consistency (α = 0.92 and 0.87, respectively). Life Engagement met the convergent validity criterion with quality of life near the end of life (r = 0.62) and life completion (r = 0.60), but not with life satisfaction (r = 0.46). Death Contemplation did not meet the convergent validity criterion with preparation for end of life (r = 0.23) but demonstrated discriminant validity with death anxiety (r = -0.03). Those with high levels of double awareness (high Life Engagement and high Death Contemplation) exhibited the best quality of life and lowest distress.
conclusionsPreliminary evidence supports the validity of the DAS. Further research is needed to demonstrate its validity in diverse settings, its utility in clinical care, and its responsiveness to therapeutic interventions in the context of advanced disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.